Antibody engineering & therapeutics Europe

Warren Viricel, Chief Scientific Officer, will present:

“Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-linker”

Platform: Increasing Therapeutic Window and Enabling New Payload Modalities

June, 7 at 15:25 CEST 

Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-linker Platform: Increasing Therapeutic Window and Enabling New Payload Modalities

Hydrophilic chemical modifiers can be embedded into drug-linker constructs of antibody drug conjugates (ADCs), to “mask” the intrinsic hydrophobicity of the attached payloads. This approach delivers conjugates having increased drug-loading (drug-antibody ratios at or above 8) and enables the use of “moderately potent ADC payloads” having differentiated mechanisms of action; while improving exposure, efficacy and tolerability of the final conjugate. It will be presented a general overview of the different strategies currently under development to serve this new approach in ADC development, as well as our internal efforts to deliver a diversified pipeline of novel ADCs based on our proprietary hydrophilic polysarcosine drug-linker platform.